MAP Pharmaceuticals reports plans to price public sale of common stock

BofA Merrill Lynch assists in financing commercialization activities

By Devika Patel

Knoxville, Tenn., July 31 - MAP Pharmaceuticals, Inc. plans to price a public offering of common stock with a 15% greenshoe option, according to a preliminary prospectus supplement filed Wednesday with the Securities and Exchange Commission.

Bank of America Merrill Lynch is the bookrunner.

Proceeds will be used for general corporate purposes and commercialization activities for Levadex.

Located in Mountain View, Calif., MAP Pharmaceuticals develops innovative therapies and inhalation delivery systems to treat a range of respiratory and systemic diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.